The bipolar disorder market reached a value of USD 3.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 4.0 Billion by 2035, exhibiting a growth rate (CAGR) of 2.08% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 3.2 Billion |
Market Forecast in 2035
|
USD 4.0 Billion |
Market Growth Rate 2025-2035 | 2.08% |
The bipolar disorder market has been comprehensively analyzed in IMARC's new report titled "Bipolar Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Bipolar disorder, also known as manic-depressive illness, refers to a mental health condition that causes extreme shifts in mood, energy, and activity levels. It can be classified into several types based on the pattern and severity of symptoms, including bipolar I, bipolar II, cyclothymic, and unspecified bipolar disorder. Individuals may experience episodes of mania or hypomania, during which they feel unusually elated, irritable, or energetic, and engage in impulsive or risky behaviors. They might also go through depressive periods where they feel sad and depressed and lose interest in things they used to enjoy. In some cases, people with bipolar disorder may exhibit psychotic indications like hallucinations or delusions. The diagnosis of the ailment is typically made by a mental health professional, such as a psychiatrist or psychologist, through a comprehensive assessment of the person's symptoms, medical history, and family history. This evaluation may include a physical exam, blood investigations, and psychological tests to rule out other conditions that may cause similar indication.
The increasing cases of neurochemical imbalances, which can cause symptoms of mania or depression, are primarily driving the bipolar disorder market. Furthermore, the rising prevalence of various associated risk factors, such as genetic predisposition, trauma, stress, substance abuse, etc., is also propelling the market growth. In addition to this, the escalating utilization of antipsychotic medications, including olanzapine and risperidone, for managing manic episodes is creating a positive outlook for the market. Moreover, the inflating usage of cognitive-behavioral therapy (CBT) to assist patients in developing coping skills and identifying triggers for their symptoms, which can help them manage their condition more effectively, is also bolstering the market growth. Apart from this, the emerging popularity of electroconvulsive therapy, since it aids in lowering the indications of depression and mania in individuals with bipolar disorder, is acting as another significant growth-inducing factor. Additionally, the introduction of novel imaging technologies, such as functional magnetic resonance imaging (fMRI), for studying the brain and understanding the neural pathways associated with the ailment is expected to drive the bipolar disorder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bipolar disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for bipolar disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bipolar disorder market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current bipolar disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Saphris (Asenapine) | AbbVie Inc. |
Vraylar (Cariprazine) | AbbVie Inc. |
Zyprexa (Olanzapine) | CHEPLAPHARM Arzneimittel |
Seroquel (Quetiapine) | AstraZeneca |
Geodon (Ziprasidone) | Viatris Inc. |
NRX-101 | NRx Pharmaceuticals, Inc. |
BHV-7000 | Biohaven, Ltd. |
ABBV-932 | AbbVie Inc. |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Bipolar Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies